Ramino Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). Ramino Bio’s unique technology addresses the unmet need of several metabolic diseases in the emerging novel elevated BCAA (Branched-chain amino acid) field. With a druggable lead compound, showing efficacy in-vivo, Ramino Bio is heading preclinical stages. First-in-human studies are planned within 18 months with our lead candidate. We are committed to developing effective therapies for the benefit of the patients.